MAP2K1 and neoplasm: In conclusion, patient-derived organoids were successfully established from PARPi-resistant HGSOC cell lines, retaining the original tumor architecture and biomarker expression (EpCAM, CA125, PAX8, HER2, MEK1/2, Cyclin E1), thus validating their use as preclinical models.